Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

10.4%

8 terminated/withdrawn out of 77 trials

Success Rate

85.2%

-1.3% vs industry average

Late-Stage Pipeline

39%

30 trials in Phase 3/4

Results Transparency

28%

13 of 46 completed trials have results

Key Signals

13 recruiting13 with results7 terminated

Enrollment Performance

Analytics

N/A

29(40.3%)

Phase 3

15(20.8%)

Phase 4

15(20.8%)

Phase 2

11(15.3%)

Phase 1

2(2.8%)

72Total

N/A(29)

Phase 3(15)

Phase 4(15)

Phase 2(11)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (77)

Showing 20 of 77 trials

NCT07495852Phase 3Recruiting

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Role: lead

NCT07075718Phase 2Recruiting

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Role: lead

NCT07400926Recruiting

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Role: lead

NCT07400965Phase 2Recruiting

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Role: lead

NCT07400952Phase 2Recruiting

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Role: lead

NCT06066645Phase 3Recruiting

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

Role: lead

NCT06848946Phase 4Recruiting

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Role: lead

NCT07228221Phase 4Recruiting

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Role: collaborator

NCT05966493Phase 2Recruiting

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Role: lead

NCT04081103Phase 2Terminated

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

Role: lead

NCT06607705Not ApplicableRecruiting

Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens Sensor

Role: collaborator

NCT03519386Phase 3Completed

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Role: lead

NCT03868124Phase 3Completed

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

Role: lead

NCT06582732Phase 2Completed

Performance of the Travoprost Intraocular Implant

Role: lead

NCT05127551Not ApplicableActive Not Recruiting

Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor

Role: lead

NCT05314738Phase 1Recruiting

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

Role: lead

NCT06061718Phase 3Active Not Recruiting

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Role: lead

NCT03319082Recruiting

Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery

Role: lead

NCT04624698Not ApplicableActive Not Recruiting

iStent Inject New Enrollment Post-Approval Study

Role: lead

NCT03442751Phase 3Completed

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

Role: lead